0M61 Stock Chart & Stats
€0.84
-€0.05(-5.95%)
At close: 4:00 PM EDT
€0.84
-€0.05(-5.95%)
Day’s Range― - ―
52-Week Range€0.54 - €1.69
Previous CloseN/A
Volume0.00
Average Volume (3M)93.00
Market Cap
€33.84M
Enterprise Value€31.82
Total Cash (Recent Filing)€13.45M
Total Debt (Recent Filing)€20.08M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 11, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding38,638,653
10 Day Avg. Volume0
30 Day Avg. Volume93
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.34
Price to Sales (P/S)0.93
P/FCF Ratio-2.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.93Price Target Upside367.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.27
Revenue Forecast (FY)€38.97M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Improving Operating EfficiencySustained ~68% gross margins provide structurally attractive unit economics for a hardware-plus-service medical device. Combined with modest operating expense discipline and narrowing adjusted EBITDA, this gives the company room to invest in sales, recurring programs and product R&D while pursuing path to profitability.
Growing Recurring Revenue And Referral NetworkA near-term shift to recurring patient sources materially improves revenue predictability and lifetime value. As MyoConnect, rehab referrals and O&P partnerships scale, recurring revenue should smooth cash flows, lower sales volatility tied to one-off device sales, and support margin expansion as service penetration deepens.
Expanded Payer Coverage And International/O&P Channel GrowthMeaningful expansion of payer contracts and covered lives reduces reimbursement friction, a structural barrier to adoption for durable medical devices. Coupled with strong international and O&P channel growth, improved market access should accelerate patient authorizations and scale referral-driven demand over multiple quarters.
Bears Say
Persistent Negative Cash Flow And Cash BurnOngoing negative operating and free cash flow indicate the business is consuming capital rather than funding growth internally. Continued cash burn reduces runway, raises the likelihood of future financings that dilute equity, and constrains the company’s ability to invest consistently in commercial scale or product development without external capital.
Elevated Leverage And Weakened Balance SheetHigher debt relative to a shrinking equity base reduces balance-sheet flexibility and raises refinancing and interest-rate risk. With ongoing losses, leverage amplifies financing pressure, limits strategic optionality, and could force prioritization of near-term liquidity over long-term commercialization investments.
Long Revenue Cycle And Reimbursement DependencyA multi-month reimbursement and authorization cycle combined with reliance on payer contracts and referral program scale creates structural timing risk. Marketing and referral investments take months to convert, and Medicare/MA headwinds or channel-mix shifts can intermittently depress margins and delay cash realization from growth initiatives.
Myomo News
0M61 FAQ
What was Myomo Inc’s price range in the past 12 months?
Myomo Inc lowest stock price was €0.54 and its highest was €1.69 in the past 12 months.
What is Myomo Inc’s market cap?
Myomo Inc’s market cap is €33.84M.
When is Myomo Inc’s upcoming earnings report date?
Myomo Inc’s upcoming earnings report date is Nov 11, 2026 which is in 97 days.
How were Myomo Inc’s earnings last quarter?
Myomo Inc released its earnings results on Aug 05, 2026. The company reported -€0.078 earnings per share for the quarter, beating the consensus estimate of -€0.085 by €0.007.
Is Myomo Inc overvalued?
According to Wall Street analysts Myomo Inc’s price is currently Undervalued.
Does Myomo Inc pay dividends?
Myomo Inc does not currently pay dividends.
What is Myomo Inc’s EPS estimate?
Myomo Inc’s EPS estimate is -0.07.
How many shares outstanding does Myomo Inc have?
Myomo Inc has 38,638,653 shares outstanding.
What happened to Myomo Inc’s price movement after its last earnings report?
Myomo Inc reported an EPS of -€0.078 in its last earnings report, beating expectations of -€0.085. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Myomo Inc?
Currently, no hedge funds are holding shares in DE:0M61
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Myomo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.93 (367.67% Upside)
€3.93 (367.67% Upside)
Blogger Sentiment
Bullish
DE:0M61 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €179.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-55.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.07%
Trailing 12-Months
Company Description
Myomo Inc
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
0M61 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights steady, incremental progress: modest top-line growth (Q1 revenue +3%), improved gross margin (+100 bps), lower operating expenses (-1%), improved adjusted EBITDA (negative $2.3M vs negative $2.8M), strong shifts toward recurring revenue (49% of revenue vs 25% prior year), and robust international and O&P channel growth (international +53% YoY; U.S. O&P +79% YoY). Management provided constructive operational updates including payer contracting (covered lives up to 158M), product advances (mobile app reducing material costs ~10%, MyoPro 3 development), and a growing referral network (150+ rehab facilities, Autoboc partnership). Lowlights include continued net losses, dependency on a multi-quarter revenue cycle, macro pressures in Medicare Advantage and a decline in Medicare Part B dollar contribution, and some short-term margin pressure from higher on-site fitting costs. Overall, positive operational momentum and improving financial metrics outweigh remaining profitability and execution risks.View all DE:0M61 earnings summaries0M61 Stock 12 Month Forecast
Average Price Target
€3.93
▲(367.67% Upside)